Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C H Ohlmann

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2010
Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomyM Johannsen, M Staehler, C-H Ohlmann, et al.
Trials|March 6, 2023
DEPROMP Trial: the additive value of PSMA-PET/CT-guided biopsy for prostate cancer management in biopsy naïve men-study protocol for a randomized trialP Krausewitz, R A Bundschuh, F C Gaertner, et al.
Plos One|May 4, 2018
Survival outcomes in patients with large (≥7cm) clear cell renal cell carcinomas treated with nephron-sparing surgery versus radical nephrectomy: Results of a multicenter cohort with long-term follow-upM W W Janssen, J Linxweiler, S Terwey, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2015
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trialsK Fizazi, T W Flaig, M Stöckle, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2010
Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomyM Johannsen, M Staehler, C-H Ohlmann, et al.
Trials|March 6, 2023
DEPROMP Trial: the additive value of PSMA-PET/CT-guided biopsy for prostate cancer management in biopsy naïve men-study protocol for a randomized trialP Krausewitz, R A Bundschuh, F C Gaertner, et al.
Plos One|May 4, 2018
Survival outcomes in patients with large (≥7cm) clear cell renal cell carcinomas treated with nephron-sparing surgery versus radical nephrectomy: Results of a multicenter cohort with long-term follow-upM W W Janssen, J Linxweiler, S Terwey, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 27, 2015
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trialsK Fizazi, T W Flaig, M Stöckle, et al.
Pageof 4